FDBusiness.com

Gumlink of Denmark has strengthened its leading position in the global nutraceutical chewing gum market by acquiring a 50% stake in Canada-based Tab Labs. Chewing gum is an ideal delivery system for nutraceutical products.

Like Gumlink, Tab Labs produces gum for the B2B marker and has recently shifted its focus towards the increasingly attractive functional and nutraceutical market. Tab Labs has especially concentrated on upgrading its facilities to accommodate extremely sensitive active ingredients such as probiotics.

Gumlink is the world’s leading B2B developer and manufacturer of chewing gum. It has accumulated vast expertise and experience in the pharmaceutical industry through sister company Fertin Pharma. This allows Gumlink to create nutraceutical concepts.

Gumlink will strengthen the new joint venture by contributing its nutraceutical chewing gum capabilities. The joint venture is among the first initiatives in Gumlink’s nutraceutical strategy for the future, launched in January 2011, involving strategic collaborations with various industry partners.

“This move makes perfect sense for us, as it will provide us with a nutraceutical manufacturing and distribution platform in North America and provides access to novel technologies that when combined with our own proprietary gum technologies will enable us to offer the most potent nutraceutical chewing gum assortment,” says Soren Birn, chief executive of Gumlink. “Furthermore, Gumlink is now following our strategic pathway to maintain and further build our position as the world’s leading nutraceutical gum developer and manufacturer.”